101553Research to create point-of-care TB diagnostic prototype from ProteinLogic unique TB biomarker signature and Microtest novel rapid diagnostic platform [MicroLogic].ClosedCollaborative R&DInnovate UKTuberculosis (TB) is responsible for over four million deaths each year. Globally there were an estimated 8.9 million new cases during 2011 and it is also a concern in the UK where there are approximately nine thousand new cases each year. Early detection and treatment is important to prevent the disease from spreading. Current diagnostic tests either lack accuracy or are not affordable or accessible to most TB patients. Delayed diagnosis is associated with reduced rates of cure. Of particular concern is our inability to diagnosis extra-pulmonary disease and TB in children or to differentiate latent infection from active TB disease. The aim of this project is to develop an in vitro diagnostic device that would for the first time offer rapid diagnosis of all forms of active TB disease from a single, easy to collect sample (blood). Previous research by the applicants has revealed characteristic soluble proteins present in the blood of TB patients and we will combine a panel of these markers on a single detection device. A small consortium has been created where scientists with expertise on TB biomarkers shall work with technologists who have designed and built a platform for detection of multiple markers in blood. Additional 'known' markers reported in the scientific literature may also be used to maximise sensitivity and specificity. The device will be optimised and evaluated using samples from South Africa and India. A prospective study will be undertaken in Cape Town to validate the device in situ. The primary output will be the final research prototype of the MicroLogic point-of-care test for active tuberculosis disease. We will formulate full technical and commercial plans to exploit the results of the project.